The acquisition allows Neurocrine to offer three therapies: Ingrezza, Crenessity, and Vykat XR.
The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).
KOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved efficacy.
Apnimed will initially receive $50m at the deal’s closing.
New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients.
The investment adds to the C$200m co-investment announced with Canada and British Columbia in 2024.
The HNSCC market is projected to grow to $4.5bn in 2034, at a CAGR of 8.4%.
